logo
Share SHARE
FONT-SIZE Plus   Neg

EU Approves Vertex Pharma's KALYDECO For Cystic Fibrosis - Quick Facts

Vertex Pharmaceuticals Inc. (VRTX) said the European Commission has approved KALYDECOTM for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator or CFTR gene. KALYDECO is the first medicine to target the underlying cause of the disease in these patients.

Cystic fibrosis is a rare genetic disease caused by defective or missing CFTR proteins resulting from mutations in the CFTR gene.

KALYDECO helps the defective CFTR protein function more normally in patients with the G551D mutation. An estimated 1,100 people in Europe have the G551D mutation. The European Approval is based on positive findings from two global Phase 3 trials in which KALYDECO showed significant and sustained improvements in breathing, weight gain and other measures of disease for people ages 6 and older with this specific genetic mutation, compared to placebo.

Further, people who took KALYDECO were 55 percent less likely to have pulmonary exacerbations, or periods of worsening in the signs and symptoms of the disease that often require treatment with antibiotics and hospital visits, than those who received placebo, the company noted.

The KALYDECO approval comes two months after the European Committee for Medicinal Products for Human Use issued a positive opinion and is the first European approval for Vertex.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Live-streaming video platform Twitch said it will launch a new affiliate program for non-partnered streamers that will allow them to earn money as they broadcast on the platform. This will be similar to YouTube's Partner program and is part of Twitch's efforts to broaden its appeal. Chocolate company Hershey Co. said it will increase the visibility of nutrition information and portion options of its snacks as well as reduce the sweets' calorie count. The move is part of the company's ongoing efforts to offer a broad range of snacks and clear information in response to feedback from consumers, who are shifting to healthier foods. The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year.
comments powered by Disqus
Follow RTT